Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07513194 · ClinicalTrials.gov registry record · Phase 1
GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT)
A Phase 1 study, sponsored by Baylor College of Medicine.
- Not yet
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT07513194 is a Phase 1 study that has not yet begun recruiting, run by Baylor College of Medicine. The registered enrollment target is 21 participants.
The verdict
NCT07513194, a Phase 1 study, has not yet begun recruiting, sponsored by Baylor College of Medicine.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study is being conducted in patients with GPC3-positive brain tumors that have recurred or have not responded to standard therapy. Atypical teratoid rhabdoid tumors (ATRT) are aggressive tumors with poor outcomes and limited treatment options, particularly in young children. There is a need for new therapies that can improve outcomes while minimizing toxicity. This study evaluates a new experimental treatment using genetically engineered T cells (RADIANT-T cells) that target glypican-3 (GPC3), a protein expressed on tumor cells. These T cells are modified to express a chimeric antigen receptor (CAR) targeting GPC3, along with IL-15 and IL-21 to enhance their persistence and activity. The cells also include an inducible safety mechanism (iCasp9) that allows them to be eliminated if necessary. The purpose of this study is to determine the highest safe dose of RADIANT-T cells, evaluate their safety and side effects, assess how long they persist in the body, and determine whether they show anti-tumor activity in patients with GPC3-positive brain tumors.
Interventions
- BIOLOGICAL 21.15.GPC3-CAR T Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2044-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07513194
The ClinicalTrials.gov registry entry for NCT07513194 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 21.15.GPC3-CAR T Cells is the first listed.
NCT07513194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07513194 about?
NCT07513194 is a clinical study titled "GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT)". This study is being conducted in patients with GPC3-positive brain tumors that have recurred or have not responded to standard therapy. Atypical teratoid rhabdoid tumors (ATRT) are aggressive tumors with poor outcomes and limited treatment options, particularly in young children. There is a need for...
What is the current status of trial NCT07513194?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2026-09-01. Estimated completion is 2044-10-31.
What interventions are being tested in trial NCT07513194?
The interventions under investigation include: 21.15.GPC3-CAR T Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT07513194?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.